PBD Biotech develops Actiphage, a blood test that detects 'active', disease-causing tuberculosis infection. One quarter of the world’s population is infected with latent tuberculosis (LTBI), also known as inactive tuberculosis. One in ten people with LTBI will progress to active TB disease. It is essential to develop newer diagnostic tests with significantly increased predictive value for the development of active disease among those who are infected than the currently available tests for LTBI (WHO, 2017). At PBD Biotech, our mission is to support the scale-up of latent tuberculosis test-and-treat campaigns with Actiphage to achieve the goals of the WHO End TB strategy. Leveraging Actiphage’s unique role in detecting active TB, PBD aims to drive innovation in the novel uses for TB screening and drug management.